Patents by Inventor Jennifer Elizabeth Davoren
Jennifer Elizabeth Davoren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9856263Abstract: The present invention provides, in part, compounds of Formula (I): and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression.Type: GrantFiled: April 15, 2015Date of Patent: January 2, 2018Assignee: PFIZER INC.Inventors: David Lawrence Firman Gray, Jennifer Elizabeth Davoren, Amy Beth Dounay, Ivan Viktorovich Efremov, Scot Richard Mente, Chakrapani Subramanyam
-
Patent number: 9822097Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), age-related cognitive decline, dementia, and Parkinson's disease.Type: GrantFiled: November 11, 2016Date of Patent: November 21, 2017Assignee: PFIZER INC.Inventors: Michael Aaron Brodney, Jennifer Elizabeth Davoren, Amy Beth Dounay, Ivan Viktorovich Efremov, David Lawrence Firman Gray, Michael Eric Green, Jaclyn Louise Henderson, Chewah Lee, Scot Richard Mente, Steven Victor O'Neil, Bruce Nelsen Rogers, Lei Zhang
-
Patent number: 9745317Abstract: The present invention provides, in part, compounds of Formula (I): and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression.Type: GrantFiled: April 14, 2015Date of Patent: August 29, 2017Assignee: Pfizer Inc.Inventors: David Lawrence Firman Gray, Lei Zhang, Michael Aaron Brodney, Jennifer Elizabeth Davoren, Ivan Viktorovich Efremov, Michael Eric Green, Steven Victor O'Neil, Bruce Nelsen Rogers
-
Patent number: 9688698Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression.Type: GrantFiled: April 23, 2015Date of Patent: June 27, 2017Assignee: PFIZER INC.Inventors: David Lawrence Firman Gray, Lei Zhang, Jennifer Elizabeth Davoren, Amy Beth Dounay, Ivan Viktorovich Efremov, Scot Richard Mente, Chakrapani Subramanyam
-
Publication number: 20170165270Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof and N-oxides thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds (N-oxides thereof or or pharmaceutically acceptable salts of the compound or the N-oxides) and the uses of such compounds (N-oxides thereof or or pharmaceutically acceptable salts of the compound or the N-oxides) for the treatment of D1-mediated (or D1-associated) disorders including cognitive and motivational impairments and negative symptoms associated with illnesses such as schizophrenia, depression, bipolar disorder, Parkinson's disease, Mild cognitive impairment (MCI), Alzheimer's disease, lupus, Huntington's disease, Parkinson's, dyskinesia, ADHD, post-traumatic stress disorder, autism spectrum disorder, treatment-resistant depression, major depressive disorder (MDD), drug dependence, Tourette's syndrome, tardive dyskinesias as well as impairments assoType: ApplicationFiled: March 1, 2017Publication date: June 15, 2017Applicant: PFIZER INC.Inventors: JOTHAM WADSWORTH COE, JOHN ARTHUR ALLEN, JENNIFER ELIZABETH DAVOREN, AMY BETH DOUNAY, IVAN VIKTOROVICH EFREMOV, DAVID LAWRENCE FIRMAN GRAY, EDWARD RAYMOND GUILMETTE, ANTHONY RICHARD HARRIS, CHRIS JOHN HELAL, JACLYN LOUISE HENDERSON, SCOT RICHARD MENTE, DEANE MILFORD NASON, STEVEN VICTOR O'NEIL, CHAKRAPANI SUBRAMANYAM, WENJIAN XU
-
Patent number: 9617275Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof and N-oxides thereof; processes and intermediates for preparation of; and compositions and uses thereof. The present invention further provides D1 agonists with reduced D1R desensitization, D1 agonists with a reduced ?-arrestin recruitment activity relative to Dopamine, D1 agonists interacting significantly with the Ser188 but not significantly with the Ser202 of a D1R when binding to the D1R, D1 agonists interacting less strongly with the Asp103 and interacting less strongly with the Ser198 of a D1R when binding to the D1R, and their uses.Type: GrantFiled: August 7, 2015Date of Patent: April 11, 2017Assignee: Pfizer Inc.Inventors: Jotham Wadsworth Coe, John Arthur Allen, Jennifer Elizabeth Davoren, Amy Beth Dounay, Ivan Viktorovich Efremov, David Lawrence Firman Gray, Edward Raymond Guilmette, Anthony Richard Harris, Chris John Helal, Jaclyn Louise Henderson, Scot Richard Mente, Deane Milford Nason, Steven Victor O'Neil, Chakrapani Subramanyam, Wenjian Xu
-
Publication number: 20170057947Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g.Type: ApplicationFiled: November 11, 2016Publication date: March 2, 2017Applicant: PFIZER INC.Inventors: MICHAEL AARON BRODNEY, JENNIFER ELIZABETH DAVOREN, AMY BETH DOUNAY, IVAN VIKTOROVICH EFREMOV, DAVID LAWRENCE FIRMAN GRAY, MICHAEL ERIC GREEN, JACLYN LOUISE HENDERSON, CHEWAH LEE, SCOT RICHARD MENTE, STEVEN VICTOR O'NEIL, BRUCE NELSEN ROGERS, LEI ZHANG
-
Publication number: 20170044174Abstract: The present invention provides, in part, compounds of Formula (I): and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression.Type: ApplicationFiled: April 14, 2015Publication date: February 16, 2017Applicant: PFIZER INC.Inventors: DAVID LAWRENCE FIRMAN GRAY, LEI ZHANG, MICHAEL AARON BRODNEY, JENNIFER ELIZABETH DAVOREN, IVAN VIKTOROVICH EFREMOV, MICHAEL ERIC GREEN, STEVEN VICTOR O'NEIL, BRUCE NELSEN ROGERS
-
Publication number: 20170037049Abstract: The present invention provides, in part, compounds of Formula (I): and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression.Type: ApplicationFiled: April 15, 2015Publication date: February 9, 2017Applicant: PFIZER INC.Inventors: DAVID LAWRENCE FIRMAN GRAY, JENNIFER ELIZABETH DAVOREN, AMY BETH DOUNAY, IVAN VIKTOROVICH EFREMOV, SCOT RICHARD MENTE, CHAKRAPANI SUBRAMANYAM
-
Publication number: 20170037053Abstract: The present invention provides, in part, compounds of Formula (I) and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression.Type: ApplicationFiled: April 13, 2015Publication date: February 9, 2017Applicant: PFIZER INC.Inventors: DAVID LAWRENCE FIRMAN GRAY, LEI ZHANG, JENNIFER ELIZABETH DAVOREN, AMY BETH DOUNAY, IVAN VIKTOROVICH EFREMOV, CHEWAH LEE, SCOT RICHARD MENTE, STEVEN VICTOR O'NEIL, BRUCE NELSEN ROGERS, CHAKRAPANI SUBRAMANYAM
-
Patent number: 9527843Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof and N-oxides of the foregoing; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, salts or N-oxides, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, impulsivity, compulsive gambling, overeating, autism spectrum disorder, MCI, age-related cognitive decline, dementia, RLS, Parkinson's disease, Huntington's chorea, anxiety, depression, MDD, TRD, and bipolar disorder.Type: GrantFiled: August 6, 2015Date of Patent: December 27, 2016Assignee: PFIZER INC.Inventors: Jennifer Elizabeth Davoren, Amy Beth Dounay, Ivan Viktorovich Efremov, David Lawrence Firman Gray, Scot Richard Mente, Steven Victor O'Neil, Bruce Nelsen Rogers, Chakrapani Subramanyam, Lei Zhang
-
Patent number: 9527831Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), age-related cognitive decline, dementia, and Parkinson's disease.Type: GrantFiled: June 23, 2014Date of Patent: December 27, 2016Assignee: PFIZER INC.Inventors: Michael Aaron Brodney, Jennifer Elizabeth Davoren, Amy Beth Dounay, Ivan Viktorovich Efremov, David Lawrence Firman Gray, Michael Eric Green, Jaclyn Louise Henderson, Chewah Lee, Scot Richard Mente, Steven Victor O'Neil, Bruce Nelsen Rogers, Lei Zhang
-
Patent number: 9260455Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I, wherein the variables R1 and R2 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.Type: GrantFiled: September 9, 2013Date of Patent: February 16, 2016Assignee: Pfizer Inc.Inventors: Michael Aaron Brodney, Elizabeth Mary Beck, Christopher Ryan Butler, Jennifer Elizabeth Davoren
-
Publication number: 20160016907Abstract: The present invention provides, in part, compounds of Formula I: N-oxides thereof, and pharmaceutically acceptable salts of the compounds or N-oxides; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M1-mediated (or M1-associated) disorders including, e.g., Alzheimer's disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.Type: ApplicationFiled: July 15, 2015Publication date: January 21, 2016Applicant: PFIZER INC.Inventors: MICHAEL AARON BRODNEY, JENNIFER ELIZABETH DAVOREN, MICHELLE RENEE GARNSEY, LEI ZHANG, STEVEN VICTOR O'NEIL
-
Publication number: 20150344474Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof and N-oxides of the foregoing; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, salts or N-oxides, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, impulsivity, compulsive gambling, overeating, autism spectrum disorder, MCI, age-related cognitive decline, dementia, RLS, Parkinson's disease, Huntington's chorea, anxiety, depression, MDD, TRD, and bipolar disorder.Type: ApplicationFiled: August 6, 2015Publication date: December 3, 2015Applicant: PFIZER INC.Inventors: JENNIFER ELIZABETH DAVOREN, AMY BETH DOUNAY, IVAN VIKTOROVICH EFREMOV, DAVID LAWRENCE FIRMAN GRAY, SCOT RICHARD MENTE, STEVEN VICTOR O'NEIL, BRUCE NELSEN ROGERS, CHAKRAPANI SUBRAMANYAM, LEI ZHANG
-
Publication number: 20150344490Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof and N-oxides thereof; processes and intermediates for preparation of; and compositions and uses thereof. The present invention further provides D1 agonists with reduced D1R desensitization, D1 agonists with a reduced ?-arrestin recruitment activity relative to Dopamine, D1 agonists interacting significantly with the Ser188 but not significantly with the Ser202 of a D1R when binding to the D1R, D1 agonists interacting less strongly with the Asp103 and interacting less strongly with the Ser198 of a D1R when binding to the D1R, and their uses.Type: ApplicationFiled: August 7, 2015Publication date: December 3, 2015Applicant: PFIZER INC.Inventors: JOTHAM WADSWORTH COE, JOHN ARTHUR ALLEN, JENNIFER ELIZABETH DAVOREN, AMY BETH DOUNAY, IVAN VIKTOROVICH EFREMOV, DAVID LAWRENCE FIRMAN GRAY, EDWARD RAYMOND GUILMETTE, ANTHONY RICHARD HARRIS, CHRIS JOHN HELAL, JACLYN LOUISE HENDERSON, SCOT RICHARD MENTE, DEANE MILFORD NASON, STEVEN VICTOR O'NEIL, CHAKRAPANI SUBRAMANYAM, WENJIAN XU
-
Patent number: 9198917Abstract: The present invention provides compounds of Formula I, and the tautomers thereof, and the pharmaceutically acceptable salts of the compounds and tautomers, wherein the compounds have the structure wherein the variables R1, R2, R3, R4 and x are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.Type: GrantFiled: April 24, 2015Date of Patent: December 1, 2015Assignee: Pfizer Inc.Inventors: Michael Aaron Brodney, Elizabeth Mary Beck, Christopher Ryan Butler, Jennifer Elizabeth Davoren, Brian Thomas O'Neill
-
Patent number: 9192612Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variables R1 and R2 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.Type: GrantFiled: April 23, 2015Date of Patent: November 24, 2015Assignee: Pfizer Inc.Inventors: Michael Aaron Brodney, Christopher Ryan Butler, Elizabeth Mary Beck, Jennifer Elizabeth Davoren, Erik Alphie LaChapelle, Brian Thomas O'Neill
-
Publication number: 20150307522Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression.Type: ApplicationFiled: April 23, 2015Publication date: October 29, 2015Applicant: PFIZER INC.Inventors: DAVID LAWRENCE FIRMAN GRAY, LEI ZHANG, JENNIFER ELIZABETH DAVOREN, AMY BETH DOUNAY, IVAN VIKTOROVICH EFREMOV, SCOT RICHARD MENTE, CHAKRAPANI SUBRAMANYAM
-
Publication number: 20150291625Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof and N-oxides thereof; processes and intermediates for preparation of; and compositions and uses thereof. The present invention further provides D1 agonists with reduced D1R desensitization, D1 agonists with a reduced ?-arrestin recruitment activity relative to Dopamine, D1 agonists interacting significantly with the Ser188 but not significantly with the Ser202 of a D1R when binding to the D1R, D1 agonists interacting less strongly with the Asp103 and interacting less strongly with the Ser198 of a D1R when binding to the D1R, and their uses.Type: ApplicationFiled: October 29, 2013Publication date: October 15, 2015Inventors: JOTHAM WADSWORTH COE, JOHN ARTHUR ALLEN, JENNIFER ELIZABETH DAVOREN, AMY BETH DOUNAY, IVAN VIKTOROVICH EFREMOV, DAVID LAWRENCE FIRMAN GRAY, EDWARD RAYMOND GUILMETTE, ANTHONY RICHARD HARRIS, CHRIS JOHN HELAL, JACLYN LOUISE HENDERSON, SCOT RICHARD MENTE, DEANE MILFORD NASON, STEVEN VICTOR O'NEIL, CHAKRAPANI SUBRAMANYAM, WENJIAN XU